Physician profile
Lin Mei
NPI 1891134052
$1,089.73
in general payments reported to CMS, 2019-2025
11 companies · $68.49 in 2025
The $68.49 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $121 · 2020: $60.96 · 2021: $445 · 2022: $228 · 2023: $166 · 2025: $68.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $168 · Food and Beverage: $65.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $168.44 |
| Food and Beverage | $65.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $242.88 | 2019-2022 | |
| Janssen Biotech, INC. | $205.59 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $150.00 | 2021 | |
| Astellas Pharma US INC | $121.41 | 2023 | |
| Astrazeneca Pharmaceuticals LP | $84.74 | 2020-2025 | Imfinzi |
| Seagen INC. | $79.99 | 2021 | |
| Novartis Pharmaceuticals Corporation | $75.48 | 2021-2022 | |
| Jazz Pharmaceuticals INC. | $54.13 | 2021 | |
| Amgen INC. | $29.18 | 2022-2023 | Lumakras |
| Ethicon US, LLC | $28.93 | 2023 | Certus 140 |
| Beigene USA, INC. | $17.40 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lin Mei listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.